Thermo Fisher Scientific launches Gibco CTS Compleo fill and finish system for cell therapy manufacturing
Thermo Fisher Scientific has announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed instrument designed to streamline formulation and filling steps in cell therapy manufacturing workflows.
Addressing variability in a complex manufacturing environment
Cell therapy manufacturing presents distinctive challenges not encountered in conventional biologics production. Because therapies are frequently derived from patient cells, incoming material varies considerably in cell count, concentration, and viability. As an increasing number of cell therapies move towards commercialisation, manufacturers face mounting pressure to reduce manual intervention, tighten dose accuracy, maintain sterility, and achieve consistent batch-to-batch performance.
Formulation and filling have historically relied on manual methods that require careful handling of fragile cells in small volumes – a process that introduces variability and heightens contamination risk. The CTS Compleo system is designed to address these vulnerabilities directly through automation and a functionally closed architecture.
System design and integration
The CTS Compleo system is compact and platform-agnostic, enabling integration with existing cell processing technologies, including the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System. It sits within the broader Gibco Cell Therapy Systems (CTS) portfolio, which encompasses instruments, consumables and software, GMP-manufactured media and reagents, and viral vector systems. Gibco PeproGMP growth factors and cytokines complement the portfolio to support GMP-compliant, closed-system manufacturing across the workflow.
Thermo Fisher also offers comprehensive implementation services, including installation, application and process development support, and global service coverage.
Industry response
“We’re excited to bring forward a solution that addresses one of the biggest bottle-necks in cell therapy manufacturing, manual fill and finish,” said Tiffani Manolis, vice president and general manager, cell biology, Thermo Fisher Scientific. “By combining automation with a functionally closed design, the Gibco CTS Compleo system has the ability to streamline workflows, improve consistency, and help customers accelerate the delivery of life-changing therapies to patients.”
Early adopters report practical benefits in development settings. “The Compleo system offers a platform for closed formulation and fill that can be easily integrated into existing autologous cell therapy processes,” said Ryan Zapata, Senior Process Engineer at Arsenal Biosciences, Inc. “The intuitive protocol builder software allows for flexibility and rapid iteration in the development environment, enabling use across programs.”
For more information, visit: thermofisher.com/compleo
Digital issue: Please click here for more information
